Q (sonnet): For patients with the EML4-ALK fusion gene in lung cancer how do the different fusion variants affect their long-term quality of life and risk of developing a secondary cancer?

═ answer (success)
This question falls outside what cBioPortal data can address, and part of it also falls outside what I can responsibly answer at all.

**On quality of life and secondary cancer risk by EML4-ALK fusion variant:**
cBioPortal does not contain longitudinal quality-of-life instruments (e.g., PRO/QOL survey data) or long-term secondary malignancy surveillance data linked to specific ALK fusion breakpoint variants (e.g., variant 1/E13;A20 vs. variant 3a/b/E6;A20, etc.). The database holds genomic alteration calls, treatment/timeline events (where available per study), and overall/disease-free survival — but not QOL metrics or secondary-cancer incidence stratified by fusion variant. This would require clinical literature/registry studies (e.g., published ALK-variant outcome cohorts), not this database.

**On clinical interpretation more broadly:**
I can help you visualize the relevant data in cBioPortal, but this is for research purposes only. I cannot offer clinical advice, prognosis, or interpretation about individual patient risk or long-term outcomes.

**What I *can* do with cBioPortal data:**
- Identify studies with EML4-ALK fusion calls and pull sample/patient counts
- Break down cases by structural variant/fusion breakpoint if annotated in a specific study
- Show available survival data (OS/DFS/PFS) for ALK-fusion-positive vs. negative cohorts, with proper Kaplan-Meier caveats
- Check for treatment/timeline event data in lung cancer studies with ALK fusions

Would you like me to pull up lung cancer studies with ALK fusion data (e.g., TCGA LUAD, MSK cohorts) and show what survival/fusion-variant annotation is actually available? I'd need to confirm which studies have fusion-level breakpoint granularity before making any claims.